Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:00:20 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



Q:VBIV - VBI VACCINES INC CDA - http://www.vbivaccines.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VBIV - Q0.50.58·0.594.30.5826+0.01312.382.6392370.562  0.59  0.5573.47  0.4516:25:19Apr 3015 min RT 2¢

Recent Trades - Last 10 of 237
Time ETExPriceChangeVolume
16:25:19Q0.590.020597
16:00:01Q0.58260.013173
16:00:01Q0.58260.013128
16:00:01Q0.58260.01311,813
16:00:01Q0.58260.01312
16:00:01Q0.58260.013127
16:00:01Q0.58260.013131
16:00:01Q0.58260.013133
16:00:01Q0.58260.013137
16:00:01Q0.58260.013140

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-30 02:43U:VBIVSEDAR Annual ReportSEDAR Annual Report
2024-04-16 23:03U:VBIVSEDAR Audited Annual Financial StatementsSEDAR Annual Report
2024-04-16 23:00U:VBIVSEDAR MD & ASEDAR MD & A
2024-04-16 08:00U:VBIVNews ReleaseVBI Vaccines Reports Full Year 2023 Financial Results
2024-04-11 16:05U:VBIVNews ReleaseVBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2024-04-09 14:45U:VBIVNews ReleaseVBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2024-04-03 08:00U:VBIVNews ReleaseVBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
2024-04-02 08:00U:VBIVNews ReleaseVBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
2024-02-14 07:00U:VBIVNews ReleaseVBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
2023-11-20 08:00U:VBIVNews ReleaseVBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting
2023-11-14 20:35U:VBIVSEDAR Interim MD & ASEDAR Interim MD & A
2023-11-14 20:29U:VBIVSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-11-14 16:05U:VBIVNews ReleaseVBI Vaccines Reports Third Quarter 2023 Financial Results
2023-10-26 08:00U:VBIVNews ReleaseVBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program
2023-09-27 07:30U:VBIVNews ReleaseVBI Vaccines ¢ € ™ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern
2023-09-07 08:00U:VBIVNews ReleaseVBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM
2023-09-06 08:00U:VBIVNews ReleaseVBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFN Ž ± for the Treatment of Chronic Hepatitis B
2023-08-14 08:35U:VBIVSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-08-14 08:00U:VBIVNews ReleaseVBI Vaccines Reports Second Quarter 2023 Financial Results
2023-07-24 08:00U:VBIVNews Release ‚  VBI Vaccines Announces Closing of Underwriters ¢ € ™ Partial Exercise of Option to Purchase Additional Common Shares